Ontology highlight
ABSTRACT:
SUBMITTER: Palladini G
PROVIDER: S-EPMC3659931 | biostudies-literature | 2013 Mar
REPOSITORIES: biostudies-literature
Palladini Giovanni G Russo Paola P Milani Paolo P Foli Andrea A Lavatelli Francesca F Nuvolone Mario M Perlini Stefano S Merlini Giampaolo G
Haematologica 20120914 3
Immune-modulatory drugs are active in immunoglobulin light-chain amyloidosis and the addition of alkylating agents can potentiate their action. In this phase II prospective trial we used cyclophosphamide, lenalidomide and dexamethasone in the treatment of 21 patients who were refractory (n=13, 62%) or relapsed (n=8, 38%) after prior treatment including melphalan in all cases, bortezomib in 4 and thalidomide in 6. Median number of cycles administered was 4 (range 2-9 cycles). Severe adverse event ...[more]